The independent journey of biotechnology firm 2Seventy Bio has concluded following its full acquisition by pharmaceutical giant Bristol Myers Squibb. The deal, which resulted in the immediate delisting of 2Seventy Bio from the Nasdaq exchange, provided shareholders with a definitive cash exit of $5.00 per share.
Transaction Details and Shareholder Returns
On May 13, 2025, Bristol Myers Squibb formally completed the acquisition of all outstanding 2Seventy Bio shares in an all-cash transaction valued at $5.00 per share. This price represented a substantial 88% premium over the closing price of $2.66 recorded on March 7, 2025, just before initial deal announcements surfaced. For investors in the specialized cell therapy sector, which has faced significant market challenges, this transaction provided a certain exit valuation.
Trading in 2Seventy Bio shares was permanently halted upon deal completion.
Strategic Rationale Behind the Acquisition
The primary driver for Bristol Myers Squibb’s acquisition centers on gaining complete control over Abecma, a crucial CAR-T cell therapy developed for multiple myeloma treatment. Previously, both companies had collaborated on the development and commercialization of this therapeutic asset.
Should investors sell immediately? Or is it worth buying 2Seventy Bio?
This consolidation not only streamlines operational management but significantly strengthens Abecma’s competitive positioning within an increasingly crowded marketplace. With competing treatments such as Johnson & Johnson’s Carvykti entering the market, Bristol Myers Squibb can now deploy its extensive resources toward further development and marketing without partnership complexities.
Financial Implications and Corporate Evolution
The total acquisition value reached approximately $286 million. After accounting for 2Seventy Bio’s estimated cash reserves, the net cost to Bristol Myers Squibb amounted to roughly $102 million.
Key transaction components:
* Final share value: $5.00 per share (cash payment)
* Deal completion: May 13, 2025
* Market status: Delisted from Nasdaq
* Strategic asset: Full ownership of myeloma therapy Abecma
This acquisition represents the logical culmination of 2Seventy Bio’s strategic direction, following the company’s earlier divestment of other research programs to entities including Regeneron and Novo Nordisk. That previous restructuring had already positioned Abecma as the company’s exclusive focus, making the complete integration into Bristol Myers Squibb the natural progression.
Ad
2Seventy Bio Stock: Buy or Sell?! New 2Seventy Bio Analysis from February 7 delivers the answer:
The latest 2Seventy Bio figures speak for themselves: Urgent action needed for 2Seventy Bio investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
2Seventy Bio: Buy or sell? Read more here...
